tbuckley/cabot-search huggingface dataset:
Preoperative MRI to plan infrapatellar fat pad resection during total knee arthroplasty
Authors: Matthew J Binks, R Vlok, R Holyoak, T Melhuish, L White
Journal: Annals of the Rheumatic Diseases (2017)

We thank Pan et al for their initial paper1 and subsequent response to our comment.2–4 We agree with the proposed biphasic role of the infrapatellar fat pad (IPFP). Although there is evidence to support a change of practice towards preservation of the IPFP,5 we agree that there should not be a ‘one shoe fits all approach’, there being cases in which benefit may be …
LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab
Authors: Laura Bonanno, Angela De Paoli, Elisabetta Zulato, Giovanni Esposito, Fiorella Calabrese, Adolfo Favaretto, Antonio Santo, Alessandro Del Conte, Marco Chilosi, Francesco Oniga, Gabriella Sozzi, Massimo Moro, Francesco Ciccarese, Giorgia Nardo, Roberta Bertorelle, Cinzia Candiotto, Gian Luca De Salvo, Alberto Amadori, PierFranco Conte, Stefano Indraccolo
Journal: Clinical Cancer Research (2017)

Abstract Purpose: LKB1 is a key sensor of metabolic stress, including hypoxia and glucose deprivation, two features of the tumor microenvironment exacerbated by antiangiogenic therapy. We investigated the role of LKB1 as a potential predictive marker of sensitivity to bevacizumab in advanced non–small cell lung cancer (aNSCLC). Experimental design: We retrospectively analyzed LKB1 expression by IHC in 98 samples from 125 patients with aNSCLC, including 59 patients treated with chemotherapy and 39 treated with chemotherapy plus bevacizumab. IHC intensity was recoded in two classes (negative/weak vs. moderate/intense) and correlated with outcome according to treatment arm. Patient-derived tumor xenografts (PDXs) were used to investigate mechanisms involved in preclinical models. Results: In the whole study population (125), median OS and PFS were 11.7 [95% confidence interval (CI), 9.1–15.3] and 6.7 (95% CI, 5.7–7.2) months, respectively. Differential impact of the marker on outcome of the 98 patients was highlighted according to the treatment. Patients with negative/weak LKB1 status did not have a statistically significant benefit from bevacizumab added to chemotherapy (HR for patients treated with bevacizumab: 0.89; 95% CI, 0.51–1.56; P = 0.6803), whereas patients expressing moderate/intense LKB1 and receiving bevacizumab had significant lower risk of death compared with those not receiving bevacizumab (HR, 0.26; 95% CI, 0.10–0.64; P = 0.0035). Loss of LKB1 was associated with reduced AMPK activation in PDXs and increased tumor necrosis following bevacizumab administration, highlighting impaired control of the metabolic stress caused by this antiangiogenic drug. Conclusions: Our data hint at a possible predictive impact of LKB1 expression in patients with aNSCLC treated with chemotherapy plus bevacizumab. Clin Cancer Res; 23(13); 3316–24. ©2017 AACR.
Lactoferricin, a peptide derived from bovine lactoferrin, has anti-angiogenic activity
Authors: Jamie S. Mader, David W. Hoskin
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

3027 

Angiogenesis is a complex process whereby new blood vessels form from pre-existing parental vessels. Interfering with angiogenesis is a promising anti-cancer therapy because angiogenesis is necessary for tumor growth beyond 1-2 mm in diameter due to the tumor’s need for oxygen, nutrients, and waste removal. Bovine lactoferricin (LfcinB) is a 25 amino acid peptide obtained by acid-pepsin hydrolysis of lactoferrin. Our research has shown that LfcinB selectively kills a variety of human tumor cells through the mitochondria-dependent pathway of apoptosis. Additionally, we have recently obtained evidence that supports an anti-angiogenic role for LfcinB. Basic fibroblast growth factor (bFGF)- and vascular endothelial growth factor (VEGF)-induced in vitro proliferation and migration of human umbilical vein endothelial cells (HUVECs) was inhibited by LfcinB. However, LfcinB was not cytotoxic to HUVECs. Furthermore, we have shown that LfcinB interacts with HUVECs by binding to heparin sulfate proteoglycans on the cell surface. This binding is competitively inhibited by the addition of heparan-binding growth factors, bFGF and VEGF, but not by the addition of non-heparin binding Epidermal Growth Factor (EGF). Importantly, LfcinB caused a 40% reduction in in vivo bFGF-associated angiogenesis using the matrigel model of angiogenesis. Together, these results support an inhibitory role for LfcinB in bFGF- and VEGF-induced angiogenesis through competition for heparin binding sites on the surface of HUVECs. The anti-angiogenic activity of LfcinB may therefore have possible application for the treatment of human cancers. Supported by the Nova Scotia Health Research Foundation and the Canadian Breast Cancer Foundation (Atlantic Chapter).
Imatinib Mesylate Dose Escalation Improves Disease Response in Chronic-Phase Chronic Myeloid Leukaemia Patients after Cytogenetic or Molecular Suboptimal Responses to Standard Doses of Imatinib.
Authors: Delphine Rea, Gabriel Etienne, Selim Corm, Pascale Cony-Makhoul, Martine Gardembas, Francois-Xavier Mahon, Franck Nicolini
Journal: Blood (2007)
Responses and Disease Progression in CML-CP Patients Treated with Nilotinib after Imatinib Failure Appear To Be Affected by the BCR-ABL Mutation Status and Types.
Authors: Timothy Hughes, Giuseppe Saglio, Giovanni Martinelli, Dong-Wook Kim, S. Soverini, Martin Mueller, A. Haque, N. Gallagher, Y. Shou, Jerald Radich, Susan Branford, Andreas Hochhaus
Journal: Blood (2007)
Biomechanically primed liver microtumor array as a high-throughput mechanopharmacological screening platform for stroma-reprogrammed combinatorial therapy
Authors: Lu Zhu, Xingliang Fan, Bingjie Wang, Longwei Liu, Xiaojun Yan, Lyu Zhou, Yang Zeng, Mark C. Poznansky, Lili Wang, Huabiao Chen, Yanan Du
Journal: Biomaterials (2017)
Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study
Authors: Jesus Berdeja, Sundar Jagannath, Jeffrey Zonder, Ashraf Badros, Jonathan L. Kaufman, Robert Manges, Mark Lynch, Eric Bleickardt, Prashni Paliwal, Ravi Vij
Journal: Blood (2014)
Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial
Authors: Nitin Jain, Sreyashi Basu, Philip A Thompson, Maro Ohanian, Alessandra Ferrajoli, Naveen Pemmaraju, Jorge E. Cortes, Zeev Estrov, Jan A Burger, Sattva S. Neelapu, Wanda Lopez, Beenu Thakral, Carlos E. Bueso-Ramos, Jorge Blando, Susan M. O'Brien, Hagop M. Kantarjian, James Allison, Michael Keating, Padmanee Sharma, William G. Wierda
Journal: Blood (2016)
Sorting zebrafish thrombocyte lineage cells with a Cd41 monoclonal antibody enriches hematopoietic stem cell activity
Authors: John M. Gansner, Alexander D. Leung, Michael Superdock, Megan C. Blair, Michelle B. Ammerman, Ellen M. Durand, Bruce Barut, Robert I. Handin, David L. Stachura, Chafen Lu, Timothy A. Springer, Leonard I. Zon
Journal: Blood (2017)
Randomized Controlled Ethanol Cookstove Intervention and Blood Pressure in Pregnant Nigerian Women
Authors: Donee Alexander, Amanda Northcross, Nathaniel Wilson, Anindita Dutta, Rishi Pandya, Tope Ibigbami, Damilola Adu, John Olamijulo, Oludare Morhason-Bello, Theodore Karrison, Oladosu Ojengbede, Christopher O. Olopade
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Rationale: Hypertension during pregnancy is a leading cause of maternal mortality. Exposure to household air pollution elevates blood pressure (BP).Objectives: To investigate the ability of a clean cookstove intervention to lower BP during pregnancy.Methods: We conducted a randomized controlled trial in Nigeria. Pregnant women cooking with kerosene or firewood were randomly assigned to an ethanol arm (n = 162) or a control arm (n = 162). BP measurements were taken during six antenatal visits. In the primary analysis, we compared ethanol users with control subjects. In subgroup analyses, we compared baseline kerosene users assigned to the intervention with kerosene control subjects and compared baseline firewood users assigned to ethanol with firewood control subjects.Measurements and Main Results: The change in diastolic blood pressure (DBP) over time was significantly different between ethanol users and control subjects (P = 0.040); systolic blood pressure (SBP) did not differ (P = 0.86). In subgroup analyses, there was no significant intervention effect for SBP; a significant difference for DBP (P = 0.031) existed among preintervention kerosene users. At the last visit, mean DBP was 2.8 mm Hg higher in control subjects than in ethanol users (3.6 mm Hg greater in control subjects than in ethanol users among preintervention kerosene users), and 6.4% of control subjects were hypertensive (SBP ≥140 and/or DBP ≥90 mm Hg) versus 1.9% of ethanol users (P = 0.051). Among preintervention kerosene users, 8.8% of control subjects were hypertensive compared with 1.8% of ethanol users (P = 0.029).Conclusions: To our knowledge, this is the first cookstove randomized controlled trial examining prenatal BP. Ethanol cookstoves have potential to reduce DBP and hypertension during pregnancy. Accordingly, clean cooking fuels may reduce adverse health impacts associated with household air pollution.Clinical trial registered with www.clinicaltrials.gov (NCT02394574).
The Association of Gilbert's Syndrome with Hyperbilirubinaemia Occurring on Any of Imatinib, Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukaemia (CML)
Authors: Jeeyune Bahk, Simone Claudiani, Richard M Szydlo, Sarmad Toma, Faisal Abdillah, Sandra Hing, Simona Deplano, Dragana Milojkovic, Jane F Apperley, Letizia Foroni
Journal: Blood (2015)
The Frequency of Detection of BCR-ABL Mutations in Imatinib Treated Patients with Chronic Phase CML Who Attain a Complete Cytogenetic Response (CCR) Does Not Diminish with Increasing Duration of CCR but the Associated Loss of Response Is Usually Gradual.
Authors: Susan Branford, Z. Rudzki, A. Grigg, J. Seymour, P. Browett, K. Taylor, R. Herrmann, A. Schwarer, C. Arthur, K. Lynch, T. Hughes
Journal: Blood (2004)
Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia
Authors: Tilmann Bochtler, Martin Granzow, Friedrich Stölzel, Christina Kunz, Brigitte Mohr, Mutlu Kartal-Kaess, Katrin Hinderhofer, Christoph E. Heilig, Michael Kramer, Christian Thiede, Volker Endris, Martina Kirchner, Albrecht Stenzinger, Axel Benner, Martin Bornhäuser, Gerhard Ehninger, Anthony D. Ho, Anna Jauch, Alwin Krämer
Journal: Blood (2017)
Psychological Outcome after Hematopoietic Cell Transplantation for Sickle Cell Disease.
Authors: Jerome Pradere, Elise Drain, Olivier Taieb, Francoise Bernaudin, Marie Champion, Doris Bonnet, Benoit Dutray, Tahar Abbal, Geraldine Chaudre, Mathieu Kuentz, Lena Coic, Eliane Gluckman, Mariane de Montalembert, Nathalie Dhedin, Jean-Paul Vernant, Malika Benkerrou, Yves Bertrand, Jean-Pierre Vannier, Dominique Steschenko, Pierre Bordigoni, Dora Bachir, Frederic Galacteros, Jean-Laurent Casanova, Alain Fischer, Marie Rose
Journal: Blood (2005)
The use of bioelectrical impedance spectroscopy (BIS) to detect subclinical changes potentially associated with the development of breast cancer-related lymphedema.
Authors: Frank Vicini, Douglas W. Arthur, Maureen Lyden, Chirag Shah
Journal: Journal of Clinical Oncology (2012)

89 Background: The purpose of the study was to evaluate bioelectrical impedance spectroscopy's (BIS) ability to detect and monitor extracellular fluid accumulation of the upper limb as it relates to the extent of locoregional therapy for patients with breast cancer. Methods: A total of 125 patients from 4 clinical practices, with newly diagnosed breast cancer were evaluated at baseline and following locoregional procedures that could potentially affect fluid accumulation in the arm and signal the possible development of early lymphedema. In order to assess the ability of BIS to detect sub-clinical changes by treatment modality, the change in L-Dex score from baseline to measurements taken within 180 days following surgery were calculated. Results: Fifty-one patients (40.8%) underwent lumpectomy and 74 (59.2%) mastectomy; 68 patients (54.4%) underwent sentinel lymph node (SLN) sampling. Sixty-five patients underwent radiation therapy (RT) with RT patients being more likely to have undergone lumpectomy (66.2% v. 3.2%, p&lt;0.001) and axillary dissection (41.5% v. 19.4%, p=0.04) compared with patients not receiving RT. However, no difference in the mean number of nodes sampled (7.7 v. 5.4, p=0.14) was noted for patients receiving RT compared with those not receiving RT. Patients receiving RT had a significantly increased change in L-Dex score (0.8 v. -2.5, p=0.03) compared with those patients not receiving RT. For all patients, ALND was associated with a significantly increased change in L-Dex score (5.0 v. 0.3, p=0.003) compared with SLN. When stratifying by the number of nodes removed, a statistically significant increase in the change in L-Dex score was noted (0.4 v. 0.4 v. 4.3 v. 6.4, p=0.04) for 0-3, 4-6, 7-10, and greater than 10 lymph nodes removed. Conclusions: In this limited analysis, L-Dex scores paralleled the extent of axillary sampling and the addition of radiation therapy; these results suggest that BIS can be used to monitor patients for the early onset of edema as differences emerged within 180 days of surgery.
A New Class of Dimeric α-Interferons (IFN-α) Made by the Dock and Lock (DNL) Method for Improved Cancer Therapy.
Authors: Edmund A. Rossi, William J. McBride, Diane L. Nordstrom, Preeti Trisal, Thomas M. Cardillo, David M. Goldenberg, Chien-Hsing Chang
Journal: Blood (2007)
IMCT-16SERIAL EVALUATION OF LYMPHOCYTE SUBSETS IN PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS TREATED WITH STANDARD RADIATION AND TEMOZOLOMIDE
Authors: Jian Campian, Anna Piotrowski, Fran Hakim, Jeremy Rose, Xiao-Yi Yan, Ronald Gress, Stuart Grossman
Journal: Neuro-Oncology (2015)

BACKGROUND: The immune system plays a significant role in cancer prevention and outcome. In high grade gliomas (HGG), severe lymphopenia is associated with shortened survival due to tumor progression. Here we report the first comprehensive study of serial changes in lymphocyte subsets in HGG following standard radiation (RT) and temozolomide (TMZ). METHODS: Adults (KPS > 60, HIV negative) with newly diagnosed HGG scheduled to receive standard RT and TMZ followed by adjuvant TMZ were eligible. Patients were enrolled at the Johns Hopkins Hospital and at Washington University. Blood was collected before beginning therapy and at weeks 6, 10, 18, and 26, and 3 months after completing adjuvant TMZ. Analysis of lymphocyte subsets was performed at NIH/NCI on a Beckman Coulter Gallios flow cytometer; T cell naive, memory and effector subsets were assessed within CD8, Treg and nonTreg CD4 T cells. Data was analyzed with FlowJo. RESULTS: All 20 patients have enrolled. Their median age is 53 years; baseline dexamethasone dose is 0.5 mg/day, and follow-up time is 9.5 months. 15% had lymphocyte counts < 1000 cells/mm3 before starting therapy. The most significant T-cell reductions were in naive CD4+ (60% of baseline at 26 weeks, p = 0.008) and CD4+ (49% of baseline at 26 weeks, p = 0.007) cells. CD8, Tregs, CD3, CD8 effector, and NK cells were less affected. B cells were also markedly reduced. The CD4 + /CD8+ ratio fell after RT/TMZ and remained low. CONCLUSIONS: This is the first comprehensive study to report serial trends in lymphocyte subsets following RT + TMZ. CD4+ and naive CD4+ T cells appear most affected and this lymphopenia is persistent after 9 months of follow up. This data provides insight into potential therapeutic approaches (i.e. IL-7) and the optimal timing for immunologic interventions in this patient population.
Wearable Technology and Long-term Weight Loss
Authors: Predrag Klasnja, Eric B. Hekler
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Trends in Incidence and Survival of Myeloid Malignancies Since 1980, in the Côte D'or Department, Burgundy, France.
Authors: Marc Maynadié, Ines Manivet, Morgane Mounier, Francine Mugneret, François Bailly, Denis Caillot, Tony Petrella, Michel Flesch, Paule Marie Carli, François Girodon
Journal: Blood (2009)
Little Evidence of the Protective Role of MTHFR Genetic Polymorfism in Acute Leukaemia and Down Syndrome in Brazil.
Authors: Crisiane W. Zanrosso, Mariana Emerenciano, Flavio Ramos, Alexandre Figueiredo, Isis Q. Magalhaes, Edinalva Leite, Vanessa Cavalcanti, Maria TC Muniz, Maria S. Pombo-de-Oliveira
Journal: Blood (2004)
Alternative Donor Hematopoietic Cell Transplantation for Patients with Fanconi Anemia.
Authors: Margaret L. MacMillan, Bruce R. Blazar, Todd E. Defor, Kathryn E. Dusenbery, Arne Slungaard, Michael R. Verneris, Jo-Anne H. Young, Heather Zierhut, Daniel J. Weisdorf, John E. Wagner
Journal: Blood (2012)
Unrelated Bone Marrow Transplantation for Adult T Cell Leukemia/Lymphoma: A Study from the Japan Marrow Donor Program.
Authors: Koji Kato, Yoshinobu Kanda, Tetsuya Eto, Tsuyoshi Muta, Hisashi Gondo, Atae Utsunomiya, Shuichi Taniguchi, Tsunefumi Shibuya, Yasuo Morishima, Shunichi Kato, Yoshihisa Kodera, Mine Harada
Journal: Blood (2005)
Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML
Authors: Giovannino Silvestri, Lorenzo Stramucci, Justin Ellis, Justine Yu, Jason Harb, Paolo Neviani, Guido Marcucci, Klara Srutova, Katerina Machova Polakova, Denis-Claude Roy, Peter Hokland, Michael W. Deininger, Ravi Bhatia, Carlo Gambacorti-Passerini, Dragana Milojkovic, Alistair G Reid, Jane F. Apperley, Ferenc Livak, Maria R. Baer, Rossana Trotta, Danilo Perrotti
Journal: Blood (2015)
Evolution of Genomic Changes and Their Significance in Myeloma.
Authors: Masood A Shammas, Herve Loiseau, Cheng Li, Leutz Buon, Samir B Amin, Parantu Shah, King Ben, Mariateresa Fulciniti, yu-Tzu Thai, Paul Richardson, Stephane Minvielle, Kenneth C. Anderson, Nikhil C. Munshi
Journal: Blood (2009)
Media portrayal of humanitarian crises
Authors: Samuel J DeFriend
Journal: BMJ (2017)

Sheather and Hawkins discuss “compassion fatigue” in relation to contemporary humanitarian crises.1 Potential solutions must consider the important role of the media, through which distant suffering is made visible. 

Compassion fatigue, if it exists, is potentially the sum of three problems. Firstly, the gap between observing human suffering and the capacity to intervene may have become so …
Targeting ALK: Precision Medicine Takes on Drug Resistance
Authors: Jessica J. Lin, Gregory J. Riely, Alice T. Shaw
Journal: Cancer Discovery (2017)

Abstract Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-rearranged malignancies, including non–small cell lung cancer. However, the clinical benefit of targeting ALK using tyrosine kinase inhibitors (TKI) is almost universally limited by the emergence of drug resistance. Diverse mechanisms of resistance to ALK TKIs have now been discovered, and these basic mechanisms are informing the development of novel therapeutic strategies to overcome resistance in the clinic. In this review, we summarize the current successes and challenges of targeting ALK. Significance: Effective long-term treatment of ALK-rearranged cancers requires a mechanistic understanding of resistance to ALK TKIs so that rational therapies can be selected to combat resistance. This review underscores the importance of serial biopsies in capturing the dynamic therapeutic vulnerabilities within a patient's tumor and offers a perspective into the complexity of on-target and off-target ALK TKI resistance mechanisms. Therapeutic strategies that can successfully overcome, and potentially prevent, these resistance mechanisms will have the greatest impact on patient outcome. Cancer Discov; 7(2); 137–55. ©2017 AACR.
Incidence Rate of Thromboembolic Events (TE) In a Prospectively Evaluated Population of Patients with Lymphoma Enrolled In First Line Treatment Clinical Trials: a Report From the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL)
Authors: Mauro Silingardi, Stefano Luminari, Elisa Barbolini, Fiorella Ilariucci, Dimitriy Arioli, Nicola Di Renzo, Carlo Visco, Maria Cristina Leone, Giovanni Bertoldero, Francesco Angrilli, Davide Favali, Francesco Merli
Journal: Blood (2010)
Use of Fuhrman grading system for Japanese patients with renal cell carcinoma.
Authors: Yoshiyuki Miyaji, Naoki Kanomata, Shin Ohira, Aya Ohbatake, Masaichiro Fujita, Kazuhiko Fukumoto, Tomohiro Fujii, Yoshimasa Jo, Teruhiko Yokoyama, Atsushi Nagai
Journal: Journal of Clinical Oncology (2012)

452 Background: In Japan, the 3-tiered system compared with the size of nuclei of normal tubule cell was adopted as the histologic criteria for tumor grading of renal cell carcinoma (RCC) in “General Rule for Clinical and Pathological Studies on Renal Cell Carcinoma”. Fuhrman grading system is first adopted in the 4th edition (April, 2011). We evaluated the impact of these pathological features on RCC survival and recurrence in Japanese patients. Methods: We identified 187 consecutive patients who underwent partial or radical nephrectomy at our institution from 1996 to 2009 for RCC. Specimens were re-reviewed by a single pathologist (NK) blinded to clinical outcome data. The data captured were histological type according to the 2004 WHO classification and conventional Fuhrman grading system. Results: Median followup was 57 months (range 5 to 181). Median age at diagnosis was 65 years. The TNM stage (7th UICC) was I in 127 cases, II in 21, III in 20 and IV in 19. A total of 24 partial and 163 radical nephrectomies were performed. Of the specimens 144 (77.0%) were clear cell carcinoma. The metastasis-free survival rates in stage I, II and III at 5 years were 89.7% ,79.8% and 52.1%, respectively (p&lt;0.001). Univariate analysis revealed that there were significant risk factors in T stage, in Furhman grade, in microscopic venous invasion, in capsular invasion and in tumor size more than 4.1cm diameter. On multivariate analysis Furhman grade (grade I and II vs. III, vs. IV) was the only significant risk factor (HR 4.35 (III vs. I and II), HR 3.33 (IV vs. I and II), p=0.037). The overall survival rates in stage I, II , III and IV at 5 years were 83.0%, 90.0%, 76.8% and 41.8%, respectively (p&lt;0.001). On multivariate analysis T stage, capsular invasion and Furhman grade (p=0.003) were the significant risk factor. Conclusions: Even Japanese patients with renal cell carcinoma undergoing nephrectomy, Fuhrman grading system is the most important predictive factor for survival and disease-free survival.